ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
Portfolio Pulse from
ImmunityBio, Inc. (NASDAQ: IBRX) has received FDA RMAT designation for its therapies ANKTIVA® and CAR-NK, aimed at reversing lymphopenia in patients undergoing chemotherapy/radiotherapy and treating advanced pancreatic cancer.
February 28, 2025 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio has been granted FDA RMAT designation for its therapies ANKTIVA® and CAR-NK, which could enhance treatment options for lymphopenia and advanced pancreatic cancer, potentially boosting the company's market position.
The FDA RMAT designation is a significant regulatory milestone that could expedite the development and review of ImmunityBio's therapies, potentially leading to earlier market entry and increased adoption. This is likely to positively impact IBRX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100